Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marike M van Beuge

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Translational Research : the Journal of Laboratory and Clinical Medicine|October 17, 2015
Wnt pathway in Dupuytren disease: connecting profibrotic signalsMarike M van Beuge, Evert-Jan P M Ten Dam, Paul M N Werker, et al.
Fibrogenesis & Tissue Repair|July 2, 2016
Matrix and cell phenotype differences in Dupuytren's diseaseMarike M van Beuge, Evert-Jan P M Ten Dam, Paul M N Werker, et al.
Journal of Cell Communication and Signaling|December 5, 2015
Further evidence of the involvement of the Wnt signaling pathway in Dupuytren's diseaseEvert-Jan P M Ten Dam, Marike M van Beuge, Ruud A Bank, et al.
The American Journal of Pathology|October 14, 2015
YAP1 Is a Driver of Myofibroblast Differentiation in Normal and Diseased FibroblastsBram Piersma, Saskia de Rond, Paul M N Werker, et al.
Pharmaceutical Research|May 10, 2015
Microsphere-Based Rapamycin Delivery, Systemic Versus Local Administration in a Rat Model of Renal Ischemia/Reperfusion InjuryJurjen Zandstra, Marike M van Beuge, Johan Zuidema, et al.
Scientific Reports|July 24, 2025
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockadeIşıl Altıntaş, Kristina B Nürmberger, Andrea Imle, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Translational Research : the Journal of Laboratory and Clinical Medicine|October 17, 2015
Wnt pathway in Dupuytren disease: connecting profibrotic signalsMarike M van Beuge, Evert-Jan P M Ten Dam, Paul M N Werker, et al.
Fibrogenesis & Tissue Repair|July 2, 2016
Matrix and cell phenotype differences in Dupuytren's diseaseMarike M van Beuge, Evert-Jan P M Ten Dam, Paul M N Werker, et al.
Journal of Cell Communication and Signaling|December 5, 2015
Further evidence of the involvement of the Wnt signaling pathway in Dupuytren's diseaseEvert-Jan P M Ten Dam, Marike M van Beuge, Ruud A Bank, et al.
The American Journal of Pathology|October 14, 2015
YAP1 Is a Driver of Myofibroblast Differentiation in Normal and Diseased FibroblastsBram Piersma, Saskia de Rond, Paul M N Werker, et al.
Pharmaceutical Research|May 10, 2015
Microsphere-Based Rapamycin Delivery, Systemic Versus Local Administration in a Rat Model of Renal Ischemia/Reperfusion InjuryJurjen Zandstra, Marike M van Beuge, Johan Zuidema, et al.
Scientific Reports|July 24, 2025
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockadeIşıl Altıntaş, Kristina B Nürmberger, Andrea Imle, et al.
Pageof 1